Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has shared an announcement.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has proposed a final ordinary cash dividend of RMB 1.45 per 10 shares for the financial year ended 31 December 2025, subject to shareholder approval at a meeting scheduled for 22 May 2026. The dividend will be paid in Hong Kong dollars on 22 July 2026, with the ex‑dividend date set for 25 May 2026 and the record date on 29 May 2026.
The company has outlined the key timetable for investors, including the last day to lodge share transfers on 26 May 2026 and a book closure period from 27 to 29 May 2026 to determine entitlements. Details on the Hong Kong dollar equivalent amount and applicable withholding tax will be announced later, signaling that some elements of the distribution mechanics and net payout to different shareholder categories are still to be clarified.
The most recent analyst rating on (HK:9989) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a Hong Kong‑listed pharmaceutical company, with its H shares traded under stock code 09989. The group operates in the healthcare and drug manufacturing sector, focusing on the development and production of pharmaceutical products for both domestic and international markets.
Average Trading Volume: 861,789
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.8B
For detailed information about 9989 stock, go to TipRanks’ Stock Analysis page.